Sanofi’s SNY stock has declined 10.2% in the past three months. However, a lot of this price decline was due to the downtrend of the overall drug and biotech sector, which performed poorly in the past ...

Despite receiving a prior wrist slap from the FDA in the shape of a Form 483, Sanofi is still working to right the ship at a ...

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines.

Sanofi is reorganising its business units from seven to five in a bid to streamline its operations and ensure the success of its ambitious product launch plans. The revamp is the first major ...

Sanofi (SNYNF – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Graham Parry from Bank ...

Sanofi’s new products like novel recombinant factor VIII therapy, Altuviiio, respiratory syncytial virus (RSV) antibody, Beyfortus (in partnership with AstraZeneca [AZN]), Pompe disease therapy ...